MedTrace Logo

Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease

NCT01313845 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2012-08-09

No results posted yet for this study

Summary

A double-blinded randomized placebo-controlled trial of intravenous amantadine on gait freezing refractory to oral anti-parkinsonian medications in patients with Parkinson's disease.

* administration of IV amantadine or normal saline for 5 days, 2 times a day while keeping current oral anti-parkinsonian medications unchanged
* follow-up after administration of IV amantadine for 4 weeks
* allocation ratio of amantadine:normal saline is 2:1

Conditions

Interventions

DRUG

amantadine sulfate

infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day

DRUG

0.9% sodium chloride

infusion of normal saline 500ml/bottle over 3 hours twice a day

Sponsors & Collaborators

  • Seoul National University Boramae Hospital

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Hanyang University

    collaborator OTHER

  • Jee-Young Lee

    lead OTHER

Principal Investigators

  • Jinwhan Cho, M.D.,Ph.D. · Department of Neurology, Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313845 on ClinicalTrials.gov